Significant correlations between AIH patient metadata (Table 2) and top PhIP-seq peptides (peptides included in analysis are summarized in Fig. 1 d, bottom panel: SEPSECS/SLA peptides 18 and 19; DIP2A peptides 58, 59, and 60; and RXFP1 peptides 4 and 5)
| Peptide (outcome) . | Metadata (predictor) . | F value . | P value . | P value, adjusteda . |
|---|---|---|---|---|
| SEPSECS/SLA peptide 19 | AIH not in biochemical remission | 14.24 | 0.00027865 | 0.00906634 |
| SEPSECS/SLA peptide 18 | AIH not in biochemical remission | 13.92 | 0.0003238 | 0.00906634 |
| SEPSECS/SLA peptide 19 | Nonsteroid treatment regimen | 8.15 | 0.00527844 | 0.07389812 |
| SEPSECS/SLA peptide 18 | Nonsteroid treatment regimen | 8.40 | 0.00465401 | 0.07389812 |
| Peptide (outcome) . | Metadata (predictor) . | F value . | P value . | P value, adjusteda . |
|---|---|---|---|---|
| SEPSECS/SLA peptide 19 | AIH not in biochemical remission | 14.24 | 0.00027865 | 0.00906634 |
| SEPSECS/SLA peptide 18 | AIH not in biochemical remission | 13.92 | 0.0003238 | 0.00906634 |
| SEPSECS/SLA peptide 19 | Nonsteroid treatment regimen | 8.15 | 0.00527844 | 0.07389812 |
| SEPSECS/SLA peptide 18 | Nonsteroid treatment regimen | 8.40 | 0.00465401 | 0.07389812 |
Benjamini–Hochberg correction was applied to control for multiple hypothesis testing.